Biotechnology - Biotechnology, AVEO Oncology

Filter

Popular Filters

More disappointment for AVEO’s tivozanib in colorectal cancer

More disappointment for AVEO’s tivozanib in colorectal cancer

14-12-2013

There was yet another setback for US biotech firm AVEO Oncology on Friday), when the company announced…

Astellas PharmaAVEO OncologyBiotechnologyOncologyResearch

Negative FDA news for AVEO's tivozanib and Dynavax' hep B vaccine

11-06-2013

US biotech firm AVEO Oncology (Nasdaq: AVEO) says that it has received a complete response letter from…

Anti-viralsAstellas PharmaAVEO OncologyBiotechnologyDynavax TechnologiesHeplisavNorth AmericaOncologyPharmaceuticalRegulationtivozanibVaccines

AVEO Oncology restructuring and job cuts as tivozanib future in RCC in doubt

05-06-2013

Following a recent negative opinion on its lead product candidate from a Food and Drug Administration…

Astellas PharmaAVEO OncologyBiotechnologyFinancialManagementOncologyResearchtivozanib

FDA advisory votes against AVEO and Astellas' cancer drug tivozanib

03-05-2013

US biotech firm AVEO Oncology (Nasdaq: AVEO) saw its shares plunge as much as 57% in late trading yesterday…

Astellas PharmaAVEO OncologyBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationtivozanib

AVEO/Astellas' kidney cancer drug tivozanib fails to beat Nexavar

14-02-2013

US biotech AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TYO: 4503) have announced…

Astellas PharmaAVEO OncologyBayerBiotechnologyNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchtivozanib

AVEO and Astellas file NDA for tivozanib in kidney cancer

02-10-2012

USA-based AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TSE:4503) have submitted…

Astellas PharmaAVEO OncologyBiotechnologyNephrology and HepatologyNorth AmericaOncologyPharmaceuticalRegulationtivozanib

Back to top